Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises SEB, Handelsbanken and Nordea in connection with Trelleborg’s new issue
Mandate

Vinge advises SEB, Handelsbanken and Nordea in connection with Trelleborg’s new issue

March 23, 2009

Vinge has advised SEB, Handelsbanken and Nordea in connection with Trelleborg AB’s new issue of shares subject to pre-emption rights for the existing shareholders of approximately SEK 2.2 billion. Trelleborg is listed on NASDAQ OMX Stockholm. The issue is underwritten in its entirety by Trelleborg’s major shareholders, certain other interested parties and SEB, Handelsbanken, Nordea and DnB NOR. SEB, Handelsbanken, Nordea and DnB NOR have undertaken to underwrite approximately SEK 900 million which thus comprises approximately 40 per cent of the new issue. The detailed terms and conditions governing the new issue including the subscription price will be determined and communicated on 21 April 2009.

Ola Sandersson and Dain Nevonen advised SEB, Handelsbanken and Nordea.

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026